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Abstract 
Background: Salivary secretory disorders can be the result of a wide range of factors. Their 
prevalence and negative effects on the patient’s quality of life oblige the clinician to confront the 
issue. 
Aim: To review the salivary secretory disorders, inducing drugs and their clinical management. 
Methods: In this article, a literature search of these dysfunctions was conducted with the assis-
tance of a research librarian in the MEDLINE/PubMed Database.  
Results: Xerostomia, or dry mouth syndrome, can be caused by medication, systemic diseases 
such as Sjögren’s Syndrome, glandular pathologies, and radiotherapy of the head and neck. 
Treatment of dry mouth is aimed at both minimizing its symptoms and preventing oral complica-
tions with the employment of sialogogues and topical acting substances. Sialorrhea and drooling, 
are mainly due to medication or neurological systemic disease. There are various therapeutic, 
pharmacologic, and surgical alternatives for its management. The pharmacology of most of the 
substances employed for the treatment of salivary disorders is well-known. Nevertheless, in some 
cases a significant improvement in salivary function has not been observed after their administra-
tion.  
Conclusion: At present, there are numerous frequently prescribed drugs whose unwanted ef-
fects include some kind of salivary disorder. In addition, the differing pathologic mechanisms, and 
the great variety of existing treatments hinder the clinical management of these patients. 
The authors have designed an algorithm to facilitate the decision making process when physicians, 
oral surgeons, or dentists face these salivary dysfunctions. 
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Introduction 
Saliva is an aqueous, hypotonic solution which 
protects all the tissues of the oral cavity. It is secreted 
by the major salivary glands – the parotid, subman-
dibular or submaxillary, and sublingual. In the oral 
cavity there are also a large number of minor salivary 
glands found on the surfaces of the buccal, palatine, 
and labial mucosa, as in the tongue, sub-lingual area, 
and in the retromolar region [1]. 
The salivary gland structure is made up of acinar 
cells, accessory ducts (intercalated and intralobular), 
striated ducts, and the principal duct (Stensen, 
Wharton, Bartholin, and Rivinus) [1]. 
Both afferent and efferent stimuli modulate 
neural control of salivation. Apart from taste and 
mastication, which play a key role, the former also 
include smell, sight, and thought. Input to the solitary 
nucleus from afferent stimuli is integrated via the 
facial (VII) and glossopharyngeal (IX) nerves [2-4]. 
Parasympathetic efferent pathways for the sub-
lingual and submandibular glands are from the facial 
 
Ivyspring  
International Publisher 
Int. J. Med. Sci. 2015, Vol. 12 
 
http://www.medsci.org 
812 
nerve via the submandibular ganglion; and for the 
parotid gland from the glossopharyngeal nerve via 
the otic ganglion. The parasympathetic nervous sys-
tem, through the liberation of acetylcholine, acts upon 
the muscarinic M3 receptors and produces an abun-
dant secretion of aqueous saliva. Sympathetic 
post-ganglionic pathways are from the cervical gan-
glion of the sympathetic chain. Stimulation of the 
sympathetic nervous system by the binding of nore-
pinephrine to β-adrenergic receptors produces a 
thicker and less abundant secretion [1,4-6]. 
Saliva formation and secretion is considered to 
be a two-step process [1,7]: 
Stage 1. Secretion of the isotonic plasma-like 
primary saliva fluid takes place in the secretory end-
pieces, also called acinar cells. There is a functional 
coupling mechanism between salt and fluid secretory 
processes. Ion channels and transporters promote a 
vectorial ion transport in the secretory direction from 
the serosal (basolateral) to luminal (apical) side. Water 
movement in the salivary glands requires the trans-
cellular secretion of Cl-. The Cl- transporting proteins 
expressed at the basolateral membrane must, there-
fore, accumulate Cl at a quantity superior to its equi-
librium potential. 
Stage 2. The NaCl-rich fluid is modified during 
its passage along the duct system, where most of the 
NaCl is reabsorbed. The K+ concentration in saliva is 
higher than that found in plasma due to KHCO3 se-
cretion. The final saliva is usually hypotonic because 
the ductal epithelium is poorly permeable to water 
and, moreover, NaCl reabsorption is greater than 
KHCO3 secretion. 
Saliva is primarily made up of water (99%) and a 
number of electrolytes which include sodium, potas-
sium, calcium, magnesium, bicarbonate, and phos-
phate. In addition, there are organic components: 
immunoglobulins (IgA, IgG, IgM), proteins, enzymes, 
mucins, and nitrogenized products (urea and ammo-
nium). The pH values of this biological fluid basically 
vary from 6 to 7. Whilst saliva is initially isotonic, 
during its ductal trajectory it becomes hypotonic. We 
can distinguish between glandular saliva, which 
comes directly from a gland, and total saliva or oral 
fluid, glandular saliva with contaminating elements 
from the mouth itself [1,5,8,9]. The latter has an effect 
on the oral cavity structures and plays a role in diges-
tion (Table 1) [8,10]. 
The major glands are primarily responsible for 
salivary volume and electrolyte content; the minor 
ones produce a smaller quantity with a high content 
of substances from the ABO blood group, neutrophils 
and other leukocytes [8]. Over 90% of unstimulated 
salivary secretion is produced by the major salivary 
glands: 20% from the parotid glands, 65% from the 
submandibular ones, 7-8% from the sublingual ones, 
and approximately 10% from the minor salivary 
glands. With stimulated saliva the percentages differ 
considerably, the parotid glands being responsible for 
more than 50% of secreted saliva [8]. 
 
Table 1: Saliva composition and functions: Relations and roles 
among the various salivary constituents. 
INFLUENCED 
AREAS FUNCTIONS SALIVARY CONSTITUENTS 
Teeth Inhibition of demineralization Mucins 
Remineralization / Buffering Proline-rich proteins 
Statherin 
Calcium 
Bicarbonate 
Phosphate 
Proteins 
Lubrication, viscoelasticity Proline-rich glycoprotein 
Mucins 
Digestion Amylase 
DNAse, RNAse 
Lipase 
Protease 
Food Taste  Zinc 
Bolus Mucins 
Antiviral Mucins 
Immunoglobulins 
Cystatins 
Microbes Antifungal Immunoglobulins 
Mucins 
Histatins 
Antibacterial Mucins 
Lysozyme 
Lactoferrin 
Lactoperoxidase 
Histatin 
Agglutinin 
Cystatins 
VEGh 
 
 
There is a wide inter-individual variation of sal-
ivary fluid rates. Values of 0.3 to 0.5 ml/min are con-
sidered normal for unstimulated salivary flow; and 
values between 0.01 and 0.1 ml/min are considered 
hyposalivation. Stimulated salivary flow is consid-
ered normal when values are from 1 to 2 ml/min; <0.7 
ml/min is considered reduced [11]. Average daily 
saliva flow is from 0.8 l to 1.5 l [1,8]. 
Sialometry encompasses a range of diagnostic 
tests aimed at evaluating the rate of salivary secretion 
(quantitative sialometry) and analyzing its composi-
tion (qualitative sialometry). When quantitative si-
alometry is employed it should be specified whether 
the saliva is mixed or uni-glandular, and whether the 
figures have been obtained at unstimulated state or 
after stimulating the secretion. Endogenous and ex-
ogenous salivary constituents are determined through 
qualitative sialometry: the former to assess physio-
logical states and diagnose salivary gland diseases 
and systemic metabolopathies, and the latter to con-
firm treatment compliance and intoxication [12]. 
Salivary secretory disorders, xerostomia and si-
alorrhea, can be caused by a wide range of factors 
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including drugs [8]. 
Xerostomia is the term used for the subjective 
sensation of dry mouth. This syndrome is a combina-
tion of signs and symptoms associated with a de-
crease in the secretion of saliva [13-15]. The reported 
prevalence of xerostomia ranges from 17-29%, and in 
a recent cross-sectional study approximately 20% was 
observed. Women have a significantly higher rate 
than men. The most frequent causes of dry mouth 
among dental patients are the use of xerogenic medi-
cations, head and neck radiotherapy, and Sjögren 
syndrome. It is generally accepted that xerostomia 
results in a lower quality of life for all affected patients 
[15-18]. 
Sialorrhea is a salivary hyper-secretion clinically 
diagnosed by quantitative sialometry. Drooling in 
many cases is not accompanied by an increased sali-
vary flow, generally the flow of saliva is normal or 
reduced and only the handling of saliva is disturbed. 
However, some drooling in infants and toddlers is 
normal and it may occur with teething [14-19]. 
To the best of our knowledge, there are no data 
concerning sialorrhea prevalence rates in the litera-
ture. However, some authors have reported a drool-
ing prevalence of approximately 14% in their control 
group, and 56% in the Parkinson’s disease one. In 
children with cerebral palsy the range of drooling 
prevalence was between 45-58% [20-23]. 
The objectives of the present review were: 
1- Study different causes of xerostomia, sialor-
rhea and drooling. 
2- Review the most important drug-effects in-
volved in these disorders. 
3- Provide a clinical approach to the current 
management strategies for these entities. 
Methods 
A literature search was conducted with the as-
sistance of a research librarian in the 
MEDLINE/PubMed Database. The primary outcome 
was to identify all literature containing original and 
review data describing (a) causes of xerostomia, si-
alorrhea and drooling, (b) the drugs related with xe-
rostomia, sialorrhea and drooling, and (c) manage-
ment strategies of these salivary gland disorders.  
The following terms were covered in the search 
were covered the terms: xerostomia (MeSH), sialor-
rhea (MeSH), drooling (MeSH), and “AND” – com-
bined with terms: “causes”, “ethiology”, “drugs”, 
“drug induced”, “Sjögren’s syndrome”, “head and 
neck radiation”, “management”, “therapy”, “bioen-
gineering” (MeSH). 
Selection of studies 
The selection of qualified studies was performed 
in three stages. First stage: assessment of the title 
alone. Second stage: based on the abstract, they were 
reviewed and irrelevant citations were removed. 
Third stage: selection based on the review of full-text 
article. The selected articles were distributed to the 
reviewer team along with a customized evaluation 
form for reviewing xerostomia, sialorrhea and drool-
ing. 
Xerostomia 
This disorder may be caused by medication, 
systemic diseases, pathologies of the salivary glands, 
and head and neck radiotherapy (Table 2) [15-24]. 
Drug induced xerostomia 
From an etiological perspective, xerostomia is 
most frequently associated with medication. It is the 
side effect of a large number of drugs and 70% of 
adults taking some kind of medication can suffer from 
it [24]. 
Anticholinergic and antimuscarinic agents are 
drugs with the capacity to reduce or block the effects 
produced by acetylcholine on the central and periph-
eral nervous system. They are generally competitive 
reversible antagonists of some of the two types of 
acetylcholine receptors, and are classified according to 
the receptor they block. Most anticholinergic agents 
affect muscarinic gland receptors producing a de-
crease in salivary secretion [5]. 
Antidepressants, such as fluoxetine, with a sero-
toninergic action have xerostomia as a common side 
effect. Xerostomia is also observed in other kinds of 
antidepressants (monoamine-oxidase inhibitors, tri-
cyclics, heterocyclics, and others) and antipsychotics, 
many of which are anticholinergic agents [5]. 
Within the group of diuretics the loop and potas-
sium-sparing ones are noteworthy as their target 
molecules include Na+, Cl- and K+, electrolytes present 
in the production-secretion process of saliva 
[15,25,26]. 
 
Table 2: Main causes underlying xerostomia. 
Drugs See table 3 
  
Systemic diseases Sjögren’s syndrome (primary and secondary) 
Granulomatous diseases (sarcoidosis, tuberculosis) 
Graft-versus-host disease 
Bone marrow transplantation 
Renal dialysis 
Malnutrition (anorexia, bulimia, dehydration) 
  
Radiation and       
radioisotopes 
External beam radiation 
Internal radionuclide therapy 
Radioactive iodine (I-131) 
Head and neck radiation 
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Table 3: Some drugs known to be associated with drug-induced 
xerostomia. 
Anticholinergic/ 
antimuscarinic agents 
Atropine, belladona, benztropine, oxybutynin, scopola-
mine, trihexyphenidyl 
  
Diuretic agents Chlorotiazide, furosemide, hydrochlorothiazide, triam-
terene 
  
Antihipertensive 
agents 
Captopril, clonidine, clonidine/chlorthalidone, enalapril, 
guanfacine, lisinopril, methyldopa 
  
Antidepressants and 
antipsychotics 
Selective serotonin-reuptake inhibitors: citalopram, 
fluoxetine, paroxetine, sertraline, venlafaxine 
Tricyclic antidepressants: imipramine, amitriptyline, 
desipramine, nortriptyline 
Monoamine oxidase inhibitors IMAO: phenelzine 
Other antidepressants: bupropion, nefazodone, 
mirtazapine  
Typical (first generation) and atypical (second generation) 
antipsychotics: haloperidol, pimozide, clozapine, 
olanzapine 
  
Antihistamines Astemizole, brompheniramine, chlorpheniramine, di-
phenhydramine, loratadine, meclizine 
  
Sedative and anxiolytic 
agents 
Alprazolam, diazepam, furazepam, temazepam, tria-
zolam 
  
Muscle relaxant agents Cyclobenzaprine, orphenadrine, tizanidine 
  
Opioids analgesic 
agents 
Central nervous system: codeine, meperidine, metha-
done, pentazocine, propoxyphene, tramadol 
  
Nonsteroidal anti- 
inflammatory agents 
Diflunisal, ibuprofen, naproxen, piroxicam 
  
Other drugs Anorexiants: diethylpropion (amfepramone), sibutramine 
Antiacne agents (retinoids): isotretinoin 
Anticonvulsants: carbamazepine 
Antidysrhythmics: disopyramide 
Anti-incontinence agent -anticholinergics-: tolterodine 
Antiparkinsonian agents: carbidopa / levodopa 
Bronchial dilators-anticholinergics-: ipratropium 
Ophthalmic formulations: brimonidine (alpha-2 adrener-
gic agonist) 
Smoking cessation agents: nicotine 
Adrenergic agents: Amphetamine 
Drugs of abuse: MDMA, cannabis 
 
 
Antihypertensive drugs such as the inhibitors of 
the angiotensin-converting enzyme (captopril and 
enalapril) may cause the accumulation of bradykin-
in-tissular mediator which is responsible for a large 
number of adverse reactions. Up to 8% of patients 
taking captopril, enalapril, and lisinopril present xe-
rostomia [27,28]. 
Anxiolytic, sedative, and opiate drugs may provoke 
xerostomia as a secondary effect in patients who are 
taking them chronically [29,32]. 
Some antihistamines, particularly those of the first 
generation and some of the third, for instance, de-
sloratadine, have an antimuscarinic effect which may 
lead to xerostomia and sedation. Second and third 
generation antihistamines effectively antagonize H1 
receptors without any special affinity for the musca-
rinic receptors [33,34]. 
A number of non-steroidal analgesic and an-
ti-inflammatory drugs (diflunisal, ibuprofen, naproxen, 
and piroxicam), anorexigens, anti-acne, anti-parkinsons, 
and anti-smoking agents amongst others, may cause a 
decrease in salivary secretion as a secondary effect 
(Table 3) [35]. 
Adrenergic agents may induce dry mouth syn-
drome. Amphetamine and MDMA (also known as 
ecstasy) can act directly or indirectly on a number of 
receptors, including the α2-adrenergic one, thus 
causing xerostomia. Occasionally, this effect may also 
lead to an acute localized periodontal pathology. 
Several reported cases of necrotizing ulcerative gin-
givitis (NUG) have been associated with the con-
sumption of MDMA. The possible mechanism may be 
due to a direct contact between the drug and the oral 
mucosa, the acid components of the tablet, and the 
dry mouth induced by MDMA [36]. 
Other illicit drugs, for example cannabis, produce 
short-term hyposalivation due to the action of del-
ta-9-tetrahydrocannabinol (THC) [37]. 
Xerostomia and Sjögren syndrome 
Sjögren Syndrome (SS) is a multisystem auto-
immune disease which causes lymphocytic infiltra-
tion in the exocrine glands, particularly the salivary 
and lacrimal ones leading to the characteristic features 
of dry eye and salivary dysfunction (xerostomia). In 
addition, approximately one third of the patients 
present systemic extraglandular manifestations [38]. 
Focal lymphocytic sialoadenitis (FLS) of the la-
bial salivary glands (minor glands) has long been as-
sociated with SS. Daniels et al. [39,40] observed that 
the focus score of FLS is strongly associated with the 
ocular and serologic components of SS and reflects SS 
autoimmunity. 
Broadly accepted classification norms were de-
veloped and validated between 1989 and 1996 by the 
European Study Group on Classification Criteria for 
SS. The most widely accepted classification criteria for 
SS are the American-European Consensus Group 
(AECG) revised version [38]. Recently, the Sjögren’s 
International Collaborative Clinical Alliance (SICCA) 
published new classification criteria following the 
American College of Rheumatology guidelines [41]. 
This consensus criticized the inclusion of subjective 
tests (symptoms), physiological measures that lack 
specificity, and alternate objective tests that are not 
diagnostically equivalent to the AECG classification 
criteria [39,41,42]. However, the final classification 
criteria might be a mix of the AECG and the SICCA. 
Head and neck radiation 
Radiotherapy (RT) of the head and neck region 
may cause acute side-effects such as mucositis, dys-
phagia, hoarseness, erythema, and desquamation of 
the skin [43,44]. Later may appear chronic injuries to 
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vasculature, salivary glands, mucosa, connective tis-
sue, and bone. The severity of these complications 
depends on radiation dosimetry, and treatment dura-
tion [45]. 
Xerostomia is the main complication in these ir-
radiated patients as it usually involves a high radia-
tion dose to both salivary gland [46]. 
Radiation-induced xerostomia has an early on-
set: in the first week, half the patients present a de-
crease in salivary flow. After 7 weeks of head and 
neck RT the salivary flow diminishes up to 20% [47]. 
Salivary function continues to decline after RT, and 
there is minimal long-term recovery [45]. 
With respect to the mean radiation dose, some 
authors have indicated that less than 25-35 Gy will 
probably prevent long-term injury. However, the is-
sue as to whether there is a threshold dose for initiat-
ing injury versus a gradual dose-complication re-
mains controversial. After head and neck RT, salivary 
glands have a limited capacity for repair especially 
with mean doses above 40 Gy [48]. 
Sialorrhea and Drooling 
Salivary hypersecretion/sialorrhea and drool-
ing, may be caused by medication, systemic diseases, 
psychiatric disorders, oral pathologies, and toxic sub-
stances (Table 4) [14]. 
In healthy subjects drugs may increase saliva 
secretion but usually not result in drooling, the pro-
duced saliva can be easily handled. On the other 
hand, drooling is generally accompanied by insuffi-
cient handling of saliva and not by hypersalivation. 
Drug-induced sialorrhea and/or drooling 
Direct muscarinic agonists are parasympathomi-
metic and, therefore, increase cholinergic tone and 
induce sialorrhea. Pilocarpine, used to treat 
wide-angle glaucoma, causes salivary hypersecretion 
as one of its adverse effects. The muscarinic agonist, 
arecoline, is an alkaloid with parasympathomimetic 
properties (see also at the end of this section the betel 
nut comment). Bethanechol is a cholinergic drug that 
selectively stimulates the parasympathetic nervous 
system across muscarinic receptors. It is sometimes 
given orally or subcutaneously to treat urinary reten-
tion resulting from a general anesthetic, diabetic 
neuropathy of the bladder, or to treat gastrointestinal 
atony (lack of muscular tone). Cevimeline is also a 
parasympathomimetic and muscarinic agonist with 
particular effect on M3 receptors [13,49]. 
 
 
 
 
 
Table 4: Main causes underlying drooling or sialorrhea. 
Drugs See table 5 
  
Neurological 
diseases 
Myasthenia gravis 
Cerebral palsy 
Facial paralysis 
Guillain-Barré syndrome 
Motor neuron disease, notable amyotrophic lateral sclerosis 
(ALS) 
Moebius syndrome 
Cerebrovascular accidents 
Parkinson’s disease 
Congenital suprabulbar palsy 
Hydrocephalus 
Hypoxic encephalopathy 
Freeman-Sheldon syndrome 
Psychosis 
Brain tumors 
Seizures 
Severe mental retardation, Down syndrome 
Worster-Drought syndrome 
Landau-Kleffner syndrome 
Encephalitis 
Angleman syndrome 
  
Systemic diseases Nasal obstruction 
Heavy metal poisoning 
Hyperhydration 
Digestive pathologies: 
Oesophageal spasms, tumors and ulcerations, gastric disorders 
accompanied by nausea and vomiting, pancreatitis, bladder 
processes, intestinal infections 
  
Oral conditions Mucosal ulcerations 
Teething 
Ulcerative lichen planus 
Herpetic ulceration 
Traumatic ulceration 
Oral pain: pulpitis, periodontitis, stomatitis 
Pharynx and tonsilar Inflammation, irritative and ulcerative 
lesions 
Table 5: Some drugs known to be associated with drug-induced 
drooling or sialorrhea. 
Direct cholinergic/ 
muscarinic agonists 
Bethanechol, pilocarpine, arecoline, cevimeline 
  
Indirect cholinergic/ 
muscarinic agonists     
(acetylcholinesterase    
inhibitors) 
Edrophonium, neostigmine, physostigmine, pyri-
dostigmine, metrifonate, donepezil, galantamine, 
rivastigmine, tacrine 
  
Antipsychotics Typical (first generation) antipsychotics: haloperidol, 
fluphenazine 
Atypical (second generation) antipsychotics: 
clozapine, risperidone, olanzapine 
Reserpine 
  
Sedative medications Anticonvulsants-antiepileptics 
Benzodiazepines 
  
Adrenergic antagonists 
(peripheral) 
Yohimbine 
  
Medications irritating the 
esophagus 
Doxycycline, tetracycline, iron preparations, quini-
dine, potassium, nonsteroidal anti-inflammatory 
drugs 
  
Poisons and toxins Heavy metals: arsenic, manganese, mercury (inor-
ganic volatile), thallium 
Organophosphates: insecticides, nerve gases (sarin, 
tabun, soman, VX) 
Food poisoning: Amanita muscaria 
Illicit drugs: phencyclidine (PCP) 
  
Herbal and fruit prepara-
tions 
Betel nut, jaborandi, yohimbine, citric acid, red 
pepper 
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Indirect muscarinic stimulants are primarily inhib-
itors of the acetylcholinesterase enzyme, they increase 
acetylcholine to stimulate muscarinic and nicotinic 
receptors which results in an increased saliva flow. 
Donepezil, galantamine, and rivastigmine, the main 
clinical acetylcholinesterase inhibitors, are used in the 
treatment of Alzheimer’s disease. Despite its compel-
ling mechanism, drooling is rarely considered to be a 
clinical problem with this class of drugs [50-52]. Other 
inhibitors of acetylcholinesterase are edrophonium, 
neostigmine, and physostigmine, mainly employed in 
the diagnosis and treatment of myasthenia gravis [53]. 
Antidopaminergic drugs can all potentially lead to 
drooling if they cause clinical bradykinesia which 
results in a low rate of swallowing. This is usually 
clinically quite evident as patients appear to have 
extrapyramidal side effects. Antipsychotic drugs can, 
therefore, produce sialorrhea due to: 
1. Induced parkinson symptoms.  
2. Blockage of the α2-adrenergic receptors or 
decrease of noradrenaline. 
3. Direct agonism of the M3 and M4 muscarinic 
receptors. 
Typical (first generation) antipsychotic drugs, 
such as haloperidol and fluphenazine, are stronger 
inducers for extrapyramidal symptoms than those of 
the atypical (second generation) antipsychotics, for 
instance clozapine, risperidone, and olanzapine. An-
other mechanism that interferes with swallowing is 
excessive sedation, a side effect of many antipsychot-
ics [13]. 
Clozapine is the atypical antipsychotic prototype. 
It can cause sialorrhea due to its agonist effect on the 
M3 and M4 glandular muscarinic receptors which 
leads to an increase in salivary secretion through the 
parasympathetic nervous system, and also because of 
its antagonism with the α2-adrenergic receptors of the 
sympathetic nervous system [54,55]. 
In some cases, benzodiazepines may cause drool-
ing, indicating a change in the underlying swallowing 
process due to excessive sedation, particularly at high 
doses [13]. 
Drooling can also result from an esophagus 
mucosal inflammation induced by tetracycline, 
doxycycline, iron preparations, quinidine, potassium, 
and non-steroidal anti-inflammatory drugs which 
might impair swallowing either functionally or from 
pain [13,14]. 
Drooling is a hallmark of some toxins such as 
organophosphate insecticides and related nerve 
agents which irreversibly block the acetylcholinester-
ase enzyme, thus producing signs and symptoms 
from the overstimulation of the muscarinic and nico-
tinic receptors. Pro-cholinergic toxins from mush-
rooms such as the muscarine (Amanita muscaria) can 
produce sialorrhea in acute intoxication. Poisoning 
from mercury, thallium, manganese, and arsenic can 
also induce drooling [56-60], and it is also a clinical 
sign of some illicit drugs such as phencyclidine (PCP) 
[13]. 
A number of preparations based on herbs, for 
instance jaborandi which contains pilocarpine, and 
yohimbine supplements (alkaloids) considered to be 
peripheral adrenergic α2 antagonists, may stimulate 
salivary secretion [61,62]. In addition, the betel nut, a 
widely used drug chewed by millions of people in 
Southeast Asia, contains arecoline a direct muscarinic 
agonist which can cause “betel nut drooling”, whilst 
both citric acid and red pepper can stimulate saliva 
flow (Table 5) [13]. 
Neurological diseases 
Drooling is often a consequence of some cen-
trally neurological disorders, as in patients affected by 
cerebral palsy or mental retardation. Nevertheless, 
there are some peripheral affections such as seventh 
or ninth cranial nerve palsies where drooling may be 
also present [63]. Furthermore, Lespargot et al. indi-
cated that drooling is related to one or more of three 
abnormalities [64]: 
• Incomplete lip closure during swallowing. 
• Low suction pressure. 
• Prolonged delay between the suction and the 
propulsion phase of the intra-oral, as opposed to 
the pharyngeal or oesophageal, stage of swal-
lowing. 
Management 
Xerostomia 
Xerostomia has clear, negative effects on 
oral-dental tissue. Some of the best known side effects 
include demineralization of tooth enamel, rampant 
decay, super-infections caused by fungal diseases 
(candidiasis), reactive gingival enlargement due to 
dehydration, and loss of salivary antimicrobial prop-
erties [15]. Xerostomia can also influence ingestion, 
swallowing, and speech articulation, thus negatively 
affecting the quality of life of people suffering from it 
[65,66]. Its high prevalence, 17-29% according to pop-
ulation samples based on salivary flow, makes it ad-
visable that its clinical management be well-known 
[15]. See the algorithm (Fig 1). 
Initial treatment of xerostomia is basically palli-
ative, minimizing symptoms and preventing oral 
complications [15,62,66]. 
• The elimination of possible factors for xerosto-
mia such as mouthwashes with an alcoholic 
content, diet sugar, and toxic habits including 
alcohol and tobacco. 
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• Preventive treatment for complications. 
If xerostomia is an unwanted consequence of 
pharmacological treatment [67,68]: 
• The possibility of alternative medication with 
different mechanism of action should be consid-
ered. 
• Reduction of the prescribed dosage may, in some 
cases, increase salivary flow. 
• There are a number of varying frequently em-
ployed drugs and strategies for the clinical 
management of these patients: sialogogic drugs, 
immunologic agents, topical medication, and 
complementary and alternative medicine [19,69]. 
Sialogogic drugs  
Sialogogic drugs are substances designed to 
stimulate salivary secretion as they have an effect on 
the systemic pathway. These drugs act upon differing 
receptor groups: 
• Direct and indirect muscarinic agonists.  
• Peripheral adrenergic α2 antagonists. 
• Centrally active agents that diminish adrenergic 
tone.  
Pilocarpine has been shown to be efficient in SS 
patients, irradiated and with bone marrow trans-
plants. Studies have reported positive results with 
respect to glandular function and improvement in 
symptoms [19,69-73]. Pilocarpine dosage is from 5 to 
10 mg 1 h before eating, 3 times a day oral route (OR). 
Onset of effects at 30 min with a duration between 2-3 
h [72]. 
Cevimeline Hydrochloride is indicated for the 
treatment of dry mouth syndrome in patients with SS. 
The recommended dosage is 30 mg 3 times a day 
(OR). In theory, cevimeline is more specific when 
acting on salivary glands and thus presents less severe 
unwanted effects [19,69,73-75]. 
Bethanechol chloride has been reported in a 
number of studies to decrease unwanted effects 
caused by antidepressant and antipsychotic drugs. It 
is administered 4 times a day in doses from 10 to 50 
mg. It has a 1h effect and its onset of action appears 30 
min after being administered (OR) [76-78]. 
Anetholetrithione has been shown in clinical 
studies to improve symptoms of xerostomia. The ha-
bitual dosage is 25mg 3 times a day [79,80]. 
Other agents have been put forward as sialo-
gogic drugs in spite of a lack of scientific evidence 
from clinical studies. They include bromhexine and 
other mucolytic agents such as guaiphenesin. In ad-
dition, substances such as herbal preparations, ne-
ostigmine, distigmine, yohimbine, nicotinic and malic 
acid have also been attributed positive effects in the 
treatment of xerostomia [19,81]. 
 
 
Figure 1. Algorithm of salivary secretory disorder management. 
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Amongst the secondary effects produced by 
cholinergic drugs employed as sialogogics the fol-
lowing are the most noteworthy: gastrointestinal al-
terations, sweating, bronchospasms, altered heart 
rate, and blurred vision. Excessive use may produce a 
contrary effect in some patients, for example sialor-
rhea and drooling. They are contraindicated or con-
sidered to be of risk for patients with bronchial asth-
ma, chronic obstructive pulmonary disease, cardiac 
disease (angina pectoris, acute myocardial infarction), 
hyperthyroidism, gastric ulcer, arterial hypertension, 
risk of intestinal obstruction, or ureteral colic 
[19,69,72,78]. 
Immunologic agents and salivary gland protectors 
Biological substances which modulate immuno-
logical response; for instance, due to the fact that they 
aid tissue regeneration of the glandular parenchyma, 
they are employed in the treatment of tissue auto-
immune-related xerostomia [82]. 
The interferons are proteins involved in a wide 
range of regulatory functions: cell proliferation and 
differentiation, enzyme induction, and the antigen 
expression of the cell surface [83]. Interferon alpha 
(IFN-α) has been proposed as an effective treatment 
for autoimmune-related xerostomia, linked to SS, in 
which the levels of salivary cytokines are altered 
leading to the destruction of glandular tissue. It could 
act as a modifier of the biological response thus im-
proving salivary gland function [83-87]. 
Rituximab is a chimeric murine/human an-
ti-CD20 monoclonal antibody [88,89]. Meijer et al., [90] 
in pilot trials involving patients with some residual 
glandular secretory potential, described that rituxi-
mab might improve subjective and objective symp-
toms related to primary SS for at least 6-9 months. 
These authors observed that no relevant improvement 
in salivary gland function can be expected in patients 
with little or no secretory potential at baseline [90]. In 
the same way, Meiners et al. [91] reported that an-
ti-CD20 therapy can be considered an effective treat-
ment option in primary SS patients. However, Ra-
mos-Casals et al. [92] concluded that larger controlled 
trials were needed to establish the efficacy of rituxi-
mab. 
Amifostine is a cytoprotective agent which acts 
as a free radical scavenger, diminishing the cell 
damage caused by radiation when administered sim-
ultaneously with RT. The benefits are, however, in-
significant [48]. 
Other treatments with dubious reliability and 
multiple secondary effects for SS-associated xerosto-
mia have been reported in the literature, for instance, 
anti-tumor necrosis factor alpha therapy (etanercept, 
abatacept, infliximab, adalimumab, certolizumab 
pegol, and golimumab), hydroxychloroquine, an-
ti-inflammatory drugs, methotrexate, hormone re-
placement, and other monoclonal antibodies 
[19,69,86,93-98]. 
Topical medication 
Salivary substitutes, local-acting salivary stim-
ulants, lubricants, and protectors. There are a num-
ber of distinct products included within this group 
such as toothpaste, mouthwash, moisturizing gel, 
chewing gum, and salivary flow stimulating tablets 
(Table 6). 
 
Table 6: Salivary substitutes, local-acting salivary stimulants, 
lubricants, and protectors. 
Pharmaceutical 
Forms 
Mouthwash 
Toothpaste 
Gel 
Spray 
Capsule 
Tablet 
Chewing gum 
 
  
Drug          
Combinations 
Olive oil, Betaine, Xylitol 
Sorbitol, Xylitol, Betaine, Allantoin, Sodium fluoride 
Betaine, Aloe Vera, Xylitol, Sodium fluoride 
Malic acid, Xylitol 
Malic acid, Xylitol, Sodium fluoride 
Triclosan, Sodium fluoride, Aloe Vera, Vitamin E 
Sorbitol, Xylitol, Sodium fluoride, Panthenol, Vitamin E 
Xylitol, Potassium chloride, calcium, magnesium 
Maltitol, Xylitol, Sorbitol, Lysozyme, Lactoferrin, Colostrum 
extract, Glucose oxidase, Aloe barbadensis, Minerals 
CPP-ACP (Casein Phosphopeptide-Amorphous Calcium Phos-
phate), Fluoride 
Lactoferrin, Lactoperoxidase, Lysozyme, Glucose oxidase, So-
dium monofluorophosphate, Fluoride, Xylitol, Aloe Vera 
Stannous Fluoride(0.4% w/w), Glycerine, hydroxyethylcellulose 
Sodium fluoride (1.1% w/w) 
 
 
They are used for the palliative treatment of pa-
tients with non-functional glandular parenchyma, 
many of them affected by SS, and for whom sialogogic 
therapy is inadequate. 
The use of sugar-free chewing gum or tablet can 
increase salivary secretion and improve the sensation 
of dry mouth together with gustatory and masticatory 
stimulation. These products can additionally be fluo-
ride, chlorhexidine, calcium phosphate, and xylitol 
releasers [99,100]. Simons et al. [101] observed in el-
derly populations the capacity of chlorhexi-
dine-xylitol releasers, through chewing, to positively 
modify cariogenic microflora. Toothpastes and gels 
with high fluoride concentrations have also been in-
troduced in the management of xerostomic patients 
[102,103]. 
Salivary substitutes are compounds which gen-
erally contain water, electrolytes, glycoproteins, car-
boxymethylcellulose, hydroxymethylcellulose, mu-
cins, sweetening enzymes, preservatives, and some 
fluoride products. They are presented as solutions, 
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gels, tablets, or spray and administered as many times 
as needed with the aim of providing a prolonged 
humidity of the oral mucosa. In European countries, 
bovine- and porcine-derived mucin-containing sub-
stitutes are used, whilst in the United States, substi-
tutes based on carboxymethylcellulose, sometimes 
accompanied by mucopolysaccharides and glycerol 
polymer gels, are employed [81,104]. Various authors 
have studied the sensation of comfort in xerosotomia 
patients comparing salivary substitutes with placebo, 
or stimulating salivary secretion with chewing gum 
[105,106]. Ship et al. [107] demonstrated that the use of 
the novel topical dry mouth products containing olive 
oil, betaine, and xylitol (Xerostom® products) signifi-
cantly increased non-stimulated whole salivary flow 
rates, reduced complaints of xerostomia, and im-
proved xerostomia-associated quality of life. 
Stewart et al. [108] evaluated the preference and 
efficacy of three products indicated to reduce xero-
stomia: a salivary substitute (with a sorbitol/xylitol 
base), and two salivary stimulants (sorbitol/xylitol 
chewing gum and acidic tablets with sorbitol). No 
significant differences were observed between the 
sialometry of these products and the control group. 
Chewing gum, however, appeared to be a greater 
stimulant and in most cases gave the most relief for 
dry mouth syndrome. 
Intraoral releasers of saliva substitutes – res-
ervoirs. These are intraoral devices designed to de-
liver a salivary substitute (Oralbalance gel®, K-Y jel-
ly®, Orthana® artificial saliva) for a prolonged period. 
Patients who habitually wear a dental prosthesis can 
have them built into the prosthetic structure [109,110]. 
Results from reviewed studies are contradictory and 
with low rates of success [111,112]. 
Neuroelectric stimulation. In recent years, 
non-pharmacological treatment based on electrost-
imulation has been developed for xerostomia [113]. 
Through the use of miniature, intraoral electrostimu-
lators with dental splints the increase of salivary se-
cretion and improvement of symptoms have been 
attempted [114,115]. Other electrostimulation systems 
such as transcutaneous electrical nerve stimulation 
(TENS) or the remote control Saliwell GenNarino de-
vice have shown an increase in salivary secretion in 
healthy patients [116,117]. 
Glandular regeneration and surgical methods 
Glandular regeneration. Mechanisms to restore 
acinar cell function through tissue engineering and 
genetic therapy have been recently studied 
[114,118,119]. Regenerative therapy involves tissue 
stem cell transplantation to grow or re-grow healthy 
organs. Its ultimate goal is to develop fully function-
ing bioengineered organs to replace lost or damaged 
organs that result from disease, injury or aging 
[118-122]. 
In glandular regeneration, the use of duct stem 
cells has been reported for salivary gland tissue repair 
[123]. Ogawa et al. [124] demonstrated the fully func-
tional regeneration of a salivary gland through the 
orthotopic transplantation of a bioengineered salivary 
gland germ in adult mice. This recent study provides 
a proof-of-concept for bioengineered salivary gland 
regeneration as a potential treatment for xerostomia. 
Surgical methods. Some authors have proposed 
a preventive surgical technique [125-128]. Jha et al. 
[127] described a submandibular duct transposition to 
the region below the chin in order to prevent radia-
tion-induced xerostomia in patients with neoplasias 
of the pharynx and larynx. 
Complementary and alternative medicine 
Medicinal herbs, such as jaborandi (which con-
tains pilocarpine), yohimbine supplements (with yo-
himbine as an active ingredient plus others alkaloids), 
betel nut (which contains arecholine a muscarinic 
agonist), citric acid, red pepper, bakumondoto, Ice-
land Moss (Cetraria islandica), and Longo Vital can all 
stimulate salivary secretion [129-132]. 
Acupuncture as a method of treatment has a 
physiological and psychological effect through the 
activation of various biological mechanisms [133-135]. 
There are, however, no randomized clinical trials 
available which can establish this method based on 
evidence [68]. 
Sialorrhea and drooling 
In patients with persistent drooling salivary in-
continence may even be accompanied by perioral 
and/or chin dermatitis, cheilitis and on occasions, 
they may experience fungal infection. In severe cases 
of salivary hypersecretion or sialorrhea, muscular 
fatigue may arise caused by continuous forced swal-
lowing due to excess saliva. Sialorrhea may function-
ally affect phonation and gustative perception. The 
pathological repercussions should also be taken into 
consideration as there is an accompanying loss of liq-
uids, electrolytes, and proteins [13,14,63]. 
There are a number of distinct therapeutical al-
ternatives which basically differ according to their 
degree of invasiveness and the administration or not 
of medication. The following strategies are the most 
frequently used: physiotherapy and neuromuscular 
re-education techniques, pharmacological therapy 
(anticholinergic drugs), complementary and alterna-
tive medicine, minimally invasive therapies, radio-
therapy, and therapeutical surgery [13,14]. See the 
algorithm (Fig 1). 
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Physiotherapy and neuromuscular re-education tech-
niques 
Oral motor therapy. Aimed at improving oral 
skills such as suction, lip closing, and tongue and 
mandibular mobility. The speech therapist plays a 
crucial role in the evaluation of existing oral motor 
skills [14]. 
Behavioral modification through biofeedback. 
Biofeedback techniques condition the patient to 
swallow on hearing auditory stimulation. Such tech-
niques have not yet been implemented in clinical 
practice [14,136]. 
Oro-facial regulation therapy. Functional ap-
pliances are employed with high success rates. In 
cases where the disorder is not completely eliminated 
it is at least reduced. This therapy can be used with 
other ones [137-141]. 
Pharmacological therapy 
The muscarinic receptor antagonists, such as at-
ropine, scopolamine (hyoscine), and glycopyrronium 
bromide inhibit salivary secretion and can, therefore, 
be employed to treat drooling. These drugs are con-
traindicated in patients with cardiac problems, glau-
coma, prostatic hypertrophy, paralytic ileus, and py-
loric obstruction. Results are still incomplete and 
there are considerable individual variations which 
can, on occasions, lead to the administration of high 
doses with the consequent appearances of severe 
secondary effects such as excessive dry mouth, con-
stipation, urinary retention, blurred vision, irritability, 
confusion, and even toxic psychosis, all of which are 
of greater risk to the patient than the sialorrhea itself 
[15,142]. 
Atropine when administered sublingually has 
the capacity to reduce drooling [143,144]. Sublingual 
release has many advantages with respect to via par-
enteral administration. Atropine is not expensive, 
does not require special skills for its administration, 
and has a reversible effect. It is contraindicated in 
patients with cognitive deterioration, dementia, and 
hallucinations [14,15]. 
Scopolamine is applied through transdermal 
patches (Scopoderm®) for therapy of nausea associ-
ated with motion sickness. Its most common un-
wanted effect is dry mouth. Scopolamine has been 
evaluated in patients with drooling, medicated with 
clozapine, suffering from cerebral lesions, cerebral 
palsy, or major oropharyngeal resection [145,146]. The 
administration of scopolamine via nebulization pro-
vides a better absorption of the drug. An 800 µg dose 
administered two/ three times a day has been re-
ported to be both effective and without side effects 
[147]. 
Reviews such as that by Jongerius et al., [148] 
which studied the efficacy of anticholinergic medica-
tion in multi-disabled children, have shown evidence 
that some anticholinergic medication is effective 
without preference for any particular one. 
Complementary and alternative medicine 
Tongue acupuncture techniques. Acupuncture 
can stimulate the complex neural network of the 
tongue thus improving salivary secretion and swal-
lowing mechanisms. Wong et al. [149] observed that it 
was a treatment without complications, well tolerated 
by children, and that it markedly improved drooling. 
Whilst this technique depends a great deal on the skill 
and experience of the practitioner, it could be an al-
ternative or complementary therapy for children with 
non-treatable drooling [14]. More longitudinal studies 
with long-term follow-up and quantitative evalua-
tions are required to determine the validity of this 
technique. 
Radiotherapy 
The application of ionizing radiation for the 
treatment of sialorrhea, with the aim of decreasing 
salivary secretion, has been studied by authors such 
as Borg et al [150]. They warned that radiotherapy in 
children should be avoided due to the risk of inducing 
malignancy, delayed growth, xerostomia, mucositis, 
dental decay, and osteoradionecrosis [150]. This 
therapy might be effective in specific disorders such 
as amyotrophic lateral sclerosis, [151] and Parkinson 
[152]. 
Minimally invasive methods 
Botulinum toxin injection. Xerostomia is one of 
the first signs of botulism [14]. Injecting botulinum 
toxin serotype A causes the inhibition of neuromus-
cular transmission it acts by blocking the release of 
acetylcholine neurotransmitter [153]. The pilot studies 
that have been carried out reported an improvement 
of the patients treated with the botulinum toxin injec-
tion in either both parotid glands or in combination 
with the submandibular ones [14,154,155]. The trial 
conducted by Lipp et al. [156] concluded that the 
greater the dose the more reduced the drooling, nev-
ertheless, the optimum dosage has yet to be estab-
lished. 
Botulinum toxin serotype B presents different 
pharmacological properties, nevertheless, its admin-
istration has been shown to be successful in decreas-
ing drooling in patients with Parkinson [157,158]. 
Photocoagulation of the salivary gland ducts. 
The concept of laser photocoagulation is based on the 
partial destruction of the gland and occlusion of the 
duct. Chang et al. [159] employed the Nd:YAG 
(1064nm) laser for the intra-ductal photocoagulation 
of both parotid glands. In their study of 48 patients 
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with cerebral palsy they reported, in most cases, a 
significant improvement in drooling with respect to 
severity and frequency. Postoperatively they ob-
served transient facial swelling in all the patients. The 
complications were infections, cystic formations, and 
hematomas, all of which were of low frequency. 
Photocoagulation of the submandibular gland ducts is 
reserved for recurrent patients or for those who have 
had unsatisfactory results from the previously men-
tioned technique. 
Surgical methods 
Surgical control of sialorrhea is the last thera-
peutical option and is recommended: 
• In moderate and persistent cases where con-
servative therapies have not been successful. 
• In severe cases where there are antecedents of 
failure or limited results from conservative 
therapies. 
• In moderate cases in which there is retarded 
cognitive development, or where conservative 
therapies were unsuccessful due to lack of 
co-operation. 
Neurectomy. Sectioning of the parasympathetic 
nerve reduces the flow of saliva. The tympanic plexus 
nerve and the tympanic cord may be sectioned, uni- 
or bilaterally, either alone or in combination with 
other procedures such as exeresis of the submandib-
ular gland [160-162]. Neurectomy of the tympanic 
cord reduces the rates of secretion from the sublingual 
and submaxillary glands, however, as an isolated 
procedure results have been shown to be insignificant 
[163]. Auditory loss could be a possible complication 
in addition to a decrease in gustative capacity in the 
anterior two-thirds of the tongue. It is, therefore, not 
recommended in patients with auditory problems 
[14,164]. Long-term results from isolated neurecto-
mies are controversial [14,165]. 
Surgical procedures on the salivary duct and 
gland. The objective of duct ligature is to obtain gland 
atrophy. There are a number of different procedures 
which include bilateral ligature of the parotid gland 
ducts combined with the exeresis of the submandib-
ular glands. This has proven to be the simplest tech-
nique with good results (85-86% success rate) as 
demonstrated in a total of 96 patients observed in 
three studies [14,166-168]. Another procedure is repo-
sitioning of the parotid gland duct to the tonsillar 
fossa, or the posterior tonsillar pillar, in order to initi-
ate the swallowing reflex together with a bilateral 
sialoadenectomy of the submandibular glands 
[14,169]. Repositioning of the submandibular duct 
carried out alone or combined is a common procedure 
with a success rate of 75%-89%. Advantages include 
its physiological characteristics and the fact that it is a 
scar-free technique with few complications. A number 
of studies have reported differing ductal reposition-
ing techniques and results. It would be of interest to 
try to relocate the saliva exit towards the base of the 
tongue in order to physiologically initiate the swal-
lowing reflex [14]. 
Conclusions 
Quantitative alterations in salivary secretion are 
frequent in clinical practice. Their prevalence and 
negative effects on the patient’s quality of life oblige 
the physician to confront the issue. 
At present, there are numerous, frequently pre-
scribed drugs whose unwanted effects include some 
kind of salivary disorder; at the same time there is 
medication for the clinical management of patients 
with these symptoms. As a result, the physician may 
feel disorientated by both the large quantity of trigger 
or influential factors for these disorders with their 
differing pathogenic mechanisms, and the great vari-
ety of existing treatments. 
The pharmacology of most of the substances 
employed for the treatment of salivary disorders is 
well-known. Nevertheless, in some cases, depending 
on the parenchymal gland affection no significant 
improvement in salivary function has been observed 
after their administration. 
In agreement with the level of scientific evidence 
which evaluates the various substances employed in 
the treatment or clinical management of patients with 
hypersalivation/xerostomia, we can conclude that 
more clinical studies are needed to evaluate the drugs, 
substances, and techniques which are presented as 
useful therapies for these pathologies. 
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